Morphine Market

The increase in prescription of painkillers for different illnesses is driving the market growth

The increase in the prescription of painkillers for a number of diseases, including cancer, cardiovascular issues, and arthritis, is predicted to hasten the market expansion between 2021 and 2028. It's also anticipated that the ageing population's health problems will fuel the growth of the morphine market. Additionally, market expansion is predicted to be fueled by the expanding patient population and the accelerating rate of market participant penetration. 

A further factor that is projected to affect the growth of the  morphine market is the increase in cancer cases and other diseases, such as cardiovascular problems. The market is expanding mostly due to the rising use of morphine as a painkiller. Morphine is one of the best methods for reducing pain. Additionally, most regions of the world permit its use in the management of severe and ongoing pain associated with complicated medical conditions.

In addition, the increased incidence of orthopaedic disorders such osteoporosis, fibromyalgia, arthritis, and elbow pain is the main driver of the expansion of the morphine market value.

Morphine is one of the most effective drugs for pain management. Additionally, it is well acknowledged that using it to treat severe and persistent pain associated with significant medical illnesses is standard practises. Osteoporosis, fibromyalgia, elbow pain, and arthritis are a few of the orthopaedic conditions that are becoming more common, which is one of the main reasons why the market for morphine is growing so quickly. In accordance with an update from the World Health Organisation released in February 2021, 1.71 billion individuals ly experience musculoskeletal issues. The most widespread kind, low back ache, affects 568 million people worldwide.

Since musculoskeletal problems are one of the leading causes of disability worldwide, the demand for its treatments is fueling the growth of the morphine market over the research period.

More than 32.5 million Americans have osteoarthritis in 2020, according to the Centres for Disease Control and Prevention. In the UK, the prevalence of osteoarthritis is constantly increasing. Furthermore, orthopaedic disorders are more prone to cause discomfort in elderly adults. As a result, the market will grow during the study period due to the predicted rise in the number of senior persons. 

As a result of the aforementioned variables, it is therefore projected that the studied market will be strongly driven during the study period. The growing number of people having surgeries has also had a favourable impact on the demand for opioids, especially for post-operative pain management, promoting quick recovery, and reducing patient issues. Additionally, the introduction of novel opioid varieties as a result of generic manufacturers' greater focus on the abuse-deterrent formulation (ADF) has increased demand for them as effective painkillers. Thus, driving the Morphine market revenue.

The Global Morphine Market Industry is poised for substantial growth, with projections indicating a market size of 17.3 USD Billion in 2024 and an anticipated increase to 32.4 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate (CAGR) of 5.88% from 2025 to 2035. Such figures underscore the increasing reliance on morphine for pain management across various healthcare settings. The market dynamics are influenced by factors such as rising chronic pain prevalence, advancements in drug formulations, and supportive regulatory frameworks. These projections highlight the potential for sustained growth within the Global Morphine Market Industry.

The Global Morphine Market Industry is significantly influenced by the rising incidence of cancer globally. As cancer rates continue to escalate, the demand for effective pain management solutions, particularly in palliative care, intensifies. Morphine remains a cornerstone in the treatment of cancer-related pain, providing essential relief for patients. The World Health Organization highlights the importance of adequate pain management in cancer care, further emphasizing morphine's role. This growing need for effective pain relief in oncology settings is likely to drive market growth, aligning with the projected CAGR of 5.88% from 2025 to 2035, indicating a robust future for the Global Morphine Market Industry.

The Global Morphine Market Industry is characterized by various trends that shape its future. These trends include the increasing focus on personalized medicine, the integration of technology in pain management, and the growing awareness of opioid stewardship. As healthcare systems evolve, there is a shift towards tailored treatment approaches that consider individual patient needs. Additionally, technology plays a crucial role in monitoring and managing pain, potentially enhancing the effectiveness of morphine therapy. These trends collectively suggest a transformative phase for the Global Morphine Market Industry, with opportunities for innovation and improved patient outcomes.

Ongoing advancements in pharmaceutical research contribute significantly to the Global Morphine Market Industry. Innovations in drug formulation and delivery systems enhance the effectiveness and safety profiles of morphine. For instance, the development of extended-release formulations allows for better management of pain over extended periods, improving patient compliance. These advancements may lead to increased prescriptions and usage of morphine, thereby driving market growth. As the industry evolves, it is likely that new research findings will further validate morphine's role in pain management, potentially increasing its market share. This dynamic environment indicates a promising trajectory for the Global Morphine Market Industry.

Regulatory bodies worldwide are increasingly recognizing the necessity of opioid therapies, including morphine, in managing severe pain. This support is reflected in updated guidelines that endorse the responsible use of opioids in clinical practice. Such regulatory frameworks aim to balance the need for effective pain relief with the imperative to mitigate risks associated with opioid misuse. As a result, the Global Morphine Market Industry is likely to benefit from a more favorable regulatory landscape, encouraging healthcare providers to prescribe morphine more confidently. This trend may contribute to the projected market growth, with estimates suggesting a rise to 32.4 USD Billion by 2035.

The Global Morphine Market Industry experiences a notable increase in demand for effective pain management solutions. As chronic pain conditions become more prevalent, healthcare providers increasingly rely on morphine as a primary analgesic. This trend is particularly evident in regions with aging populations, where the incidence of conditions such as arthritis and cancer is on the rise. In 2024, the market is projected to reach 17.3 USD Billion, reflecting the growing recognition of morphine's efficacy in managing severe pain. The increasing acceptance of opioid therapies in clinical settings further supports this demand, suggesting a robust future for the Global Morphine Market Industry.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Morphine Market dominated this market in 2022 (45.80%). The existence of significant competitors, the prevalence of chronic diseases in the region, and the well-developed healthcare infrastructure are only a few of the critical factors influencing the market's expansion. Further, the U.S. Morphine market held the largest market share, and the Canada Morphine market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. 

Figure 2:  MORPHINE MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Morphine market accounted for the healthy market share in 2022. The market is expected to grow more quickly as a result of favourable government measures and an increase in research collaboration activity, among other things. Further, the German Morphine market held the largest market share, and the U.K Morphine market was the fastest growing market in the European region

The Asia Pacific Morphine market is expected to register significant growth from 2024 - 2032. The rising incidence of chronic diseases, especially cardiovascular conditions, is one of the primary factors driving market expansion. China is anticipated to experience the fastest increase due to its expanding population, greater patient pool, and simple access to cutting-edge therapies. Rising health spending in the area is also helping to fuel the growth of the Asia Pacific morphine market. Moreover, China’s Morphine market held the largest market share and the Indian Morphine market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Morphine market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Morphine industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Morphine industry to benefit clients and increase the market sector. In recent years, the Morphine industry has offered some of the most significant advantages to medicine.

Major players in the Morphine market, including Mallinckrodt Pharmaceuticals, Alcaliber, Purdue Pharma, Sanofi Winthrop Industries, Macfarlan Smith, Sun Pharmaceutical Industries, Qinghai Pharmaceutical, Northeast Pharmaceutical Group, Pfizer Inc., Verve Health Care Ltd., Johnson Matthey Fine Chemicals, Manus Aktteva Biopharma LLP, Mayne Pharma Group Limited, Daiichi Sankyo Inc., and Taj Pharmaceuticals Limited, are attempting to increase market demand by investing in research and development Dosage Forms.

Amphastar Pharmaceuticals Inc. (Amphastar) is a specialised pharmaceutical company that develops, produces, and sells both generic and brand-name injectable, intranasal, and inhalation medications. It offers for sale pharmaceuticals with insulin as a primary component. Enoxaparin sodium injection, cosyntropin for injection, naloxone hydrochloride (HCl) injection, phytonadione injection, lidocaine jelly, amphadase hyaluronidase injection, epinephrine, naloxone, phytonadione, primatene mist, and glucagon are some of the company's best-selling products. 

Amphastar sells its goods to long-term care facilities, hospitals, clinics, and other locations that provide alternative healthcare. In the US, the UK, France, and China, the corporation sells its products through subsidiaries, specialty distributors, wholesalers, and retailers. The US city of Rancho Cucamonga is home to Amphastar's main office. The FDA authorised Amphastar Pharmaceuticals (US) to inject morphine sulphate in May 2021.

The pharmaceutical company Purdue Pharma LP (Purdue) produces pharmacologic drugs to treat and manage pain. The company creates, manufactures, and markets prescription and over-the-counter (OTC) pharmaceuticals in addition to other healthcare-related goods. Dietary supplements, laxatives, antiseptics, sedatives for sleep disorders, and prescription opioids are a few of its main product categories. 

Butrans, Hysingla, OxyContin, Senokot, Colace, Peri-Colace, Betadine, and SlowMag are just a few of the goods it offers for sale. The business also conducts clinical research on both novel and recently authorised medications. The business has locations in New Jersey and North Carolina. The US state of Connecticut, where Stamford is located, is home to the headquarters of Purdue. A patent was granted to Purdue Pharma (US) in September 2018 for an improved formulation of buprenorphine that reduces cravings and is used to treat opiate addiction, notably OxyContin addiction.